OIS@AAO 2015
[c RetroSense Therapeutics CEO Sean Ainsworth explains how the company’s optogenetic gene therapeutic can impart light sensitivity to cells in the retina, re-sensitizing it to…
Read More
IBMD is an early-stage medical device company focused in ophthalmology innovations. The company is leading the emerging, non-laser based, precision capsulotomy category through the development…
Read More
LacriScience is in late stage development of its LacriPen, a portable instrument using gold plated single-use sensors that measures osmolarity to +/- 2 mOSM/L and…
Read MoreThe company is addressing non-adherence to eyedrops in glaucoma and in ocular hypertension. There remains a true, unmet need to provide clinically relevant intraocular pressure…
Read MoreThis company, founded as a spin-out of Liquidia Technologies in 2013, began with a $25 million Series A, with the goal of developing the PRINT…
Read MoreMati is developing a punctal plug drug delivery technology for sustained drug delivery using an “L-shaped” design to deliver medications to the canalicular space. Insertion…
Read MoreThe presbyopia market is estimated to comprise more than 2 billion people by 2020. ReVision Optics has developed the Raindrop Near Vision inlay to address…
Read MoreClarVista is a privately held, clinical- and commercial-stage ophthalmology device company concentrating solely on the development of the Harmoni modular intraocular lens (IOL) system. While…
Read More
SUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.
![OIS-ANTERIOR-NEW-DATE-750x420[4300]](https://ois.net/wp-content/uploads/2020/03/OIS-ANTERIOR-NEW-DATE-750x4204300.jpg "OIS-ANTERIOR-NEW-DATE-750x420[4300]")